New Drug and Clinical Trial Rules 2019- Two Steps Forward and One Back

Published on:August 2019
Indian Journal of Pharmacy Practice, 2019; 12(3):209-214
Case Report | doi:10.5530/ijopp.12.3.45

New Drug and Clinical Trial Rules 2019- Two Steps Forward and One Back

Authors and affiliation (s):

Swati Jadhav1,*, Ravindra Ghooi2

1Symbiosis School of Biological Sciences, Symbiosis International University, Lavale, Pune, Maharashtra, INDIA.

2Scientia Clinical Services, Pune, Maharashtra, INDIA.


The government notified the New Drugs and Clinical Trial Rules on 19th March 2019, to replace Part XA and Schedule Y of the Drugs and Cosmetics Rules 1945. Many new desirable changes have been made and these will help clinical research and trials in India. However, there are discrepancies which offset some of the advantages offered by the new rules. Including timelines for many regulatory functions, is among the main advantages offered, but incorrect use of terms, duplication of rule numbers is likely to complicate the regulatory procedures. The changed classification of Ethics Committees is a welcome feature, but it is unclear why the composition recommended by ICMR is accepted for the EC for Biomedical and Health Research, but not for the one for Clinical Trials, Bioavailability and Bioequivalence Studies. The government would do well to consider the suggestions made herein and amend the New Drugs and Clinical Trial Rules 2019.

Key words: New Drugs, Clinical Trials, Ethics Committee, Compensation, Amendments.


The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmacy Practice (IJOPP) [ISSN-0974-8326] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 2008.


IJOPP uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2014 are being assigned DOIs for its permanent URLs